SAM
MLYS icon

Smartleaf Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Smartleaf Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.1K Hold
1,639
– – ﹤0.01% 1591
2026
Q1 		$38.5K Buy
1,639
+636
+63% +$18.7K ﹤0.01% 1601
2025
Q4 		$35.6K Sell
1,003
-14
-1% -$561 ﹤0.01% 1715
2025
Q3 		$40K Buy
1,017
+676
+198% +$14.6K ﹤0.01% 1497
2025
Q2 		$4.67K Sell
341
-583
-63% -$8.45K ﹤0.01% 2079
2025
Q1 		$13.5K Sell
924
-981
-51% -$11.3K ﹤0.01% 1797
2024
Q4 		$23.9K Buy
1,905
+368
+24% +$4.81K ﹤0.01% 1545
2024
Q3 		$18.3K Buy
1,537
+1,180
+331% +$14.3K ﹤0.01% 1393
2024
Q2 		$4.11K Buy
+357
New +$4.5K ﹤0.01% 1893

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Smartleaf Asset Management's MLYS Position: Q2 2026 in Review

Smartleaf Asset Management held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 1,639 shares worth $44.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1591.

Smartleaf Asset Management first reported a position in MLYS in Q2 2024 and has held it in 9 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Smartleaf Asset Management held 1,639 shares of Mineralys Therapeutics worth $44.1K as of Q2 2026.
  • Smartleaf Asset Management left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1591 holding.
  • Smartleaf Asset Management first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.